Pfizer, Inc. vs Arcus Biosciences, Inc. — Stock Comparison
Pfizer, Inc. (PFE) and Arcus Biosciences, Inc. (RCUS) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Pfizer, Inc. scores ahead of Arcus Biosciences, Inc. on Q·Score (6.2 vs 5.1 out of 10), led by Quality (6.4 vs 0.2) and Valuation (7 vs 6). Arcus Biosciences, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for RCUS (+48.2%) than for PFE (+12.6%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consistently beats earnings estimates (4/4 quarters).
⚠ earnings contracting 10% year-over-year.
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-156% margin).
Analyst Consensus
Fundamentals
Frequently Asked Questions
PFE vs RCUS: which stock scores better overall?
Based on Q·Score, Pfizer, Inc. (PFE) scores 6.2/10 versus Arcus Biosciences, Inc. (RCUS) at 5.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: PFE or RCUS?
Pfizer, Inc. (PFE) scores higher on Growth (5.1/10 vs 4.5/10). Pfizer, Inc. reports revenue growth (5.4% YoY) while Arcus Biosciences, Inc. reports (-39.3% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is PFE or RCUS more attractively valued?
Pfizer, Inc. (PFE) scores higher on Valuation (7/10 vs 6/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about PFE vs RCUS?
There are 27 analysts covering PFE with a consensus price target of $29.19, and 12 analysts covering RCUS with a consensus target of $35.75. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: PFE or RCUS?
Pfizer, Inc. (PFE) scores higher on Quality (6.4/10 vs 0.2/10). Net profit margin: PFE at 11.8%, RCUS at -156.4%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: PFE or RCUS?
Arcus Biosciences, Inc. (RCUS) scores higher on Financial Health (9.2/10 vs 7/10). Market beta: PFE at 0.29, RCUS at 0.84. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of PFE and RCUS?
Pfizer, Inc. (PFE) has a market capitalisation of $147.7B, while Arcus Biosciences, Inc. (RCUS) has a market cap of $3.0B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do PFE or RCUS pay dividends?
PFE pays a dividend yield of 6.61%, while RCUS does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →